Immunai Analysis: $275M Raised

Immunai specializes in mapping the immune system at an unprecedented scale and resolution. Their unique approach integrates multi-omic data with advanced machine learning to enhance drug discovery and development. This enables biopharmaceutical companies to make informed decisions, reducing risks and accelerating the development of immune-related therapeutics.

Identify high-impact therapeutic targets for drug development; Prioritize drug candidates based on preclinical data; Optimize clinical trials by understanding patient responses; Generate high-quality multi-omic data from samples; Validate hypotheses using functional genomics.

Partnered with top biopharmaceutical companies and research institutions; Offers a unique end-to-end workflow for drug development; Utilizes the world's largest immune-focused single-cell database.